Avid Bioservices Inc (CDMO)

[RRdog]

FTM

Front line testing had a very aberrant number in the measurment of the control arm. I have long contended that in one form or another the front line test would revert to the mean and vindicate the efficacy of bavi. I assume this may come out in the MOS numbers where measurement is difficult to obfuscate. That is all I have to comment as of now.

As far as your very fine comments on second line it sounds like you are finally crossing the Rubicon of 12 months or better and joining me on the other side. I hope this is correct and I do not want to put words in your mouth. It is getting lonely over here but it is also beautiful.

Please let me know if I can expect company with a "clear statement".

Moving on --my advice is to start turning your math and statistical ability to the "burn rate" to be discussed in the coming CC. I predict a sizable drop in the "burn rate" as Avid revenue guide lines will be raised for the 5th consecutive qtr and as the large expensive trials burn off (trials with over 50 sites).

The only new trial is for "imaging" and it is an inexpensive 1 site trial. How cool is that. PPHM gets to approach a 10-15 billion a year market with a short fuse 1 site trial. IMO that's good value for your investor dollar.

The "burn rate" is a key statistic. Focus a bit on this piece of financial data as it affects "dilution".

It is too soon to calculate whether the added Zeibel in house legal expense actually saves dollars. It may. I think mgmt and Zeibel were unfairly tarred and feathered. There are numerous distinct advantages to bringing this guy in house. One "stonehead" contributor to this board actually was close to selling his entire position because he was so off put by this development. Sanity appears to have now returned as I see stony but bullish commentary.

Best Regards,
RRdog